Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical trial
机构：[1]Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China[2]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[3]Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省肿瘤医院[4]Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China[5]The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[6]Radiotherapy Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[7]Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China[8]Jiangsu Province Hospital/the First Affiliated Hospital with Nanjing Medical University, Nanjing, China江苏省人民医院[9]The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[10]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[11]Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[12]Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China[13]Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
第一作者机构：[1]Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China
推荐引用方式(GB/T 7714)：
Zhang Wencheng,Zhang Ke,Wang Qifeng,et al.Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical trial[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA：
Zhang, Wencheng,Zhang, Ke,Wang, Qifeng,Cao, Jianzhong,Fan, Chengcheng...&Wang, Ping.(2024).Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical trial.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA：
Zhang, Wencheng,et al."Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical trial".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)
医学